New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, ... In recent years, blockbuster glucagon-like peptide 1 receptor agonist (GLP-1RA) ...

IBIO-600 is the product of an existing relationship between iBio and Boston-based AstralBio signed in March 2024 that saw the two biotechs advance a joint myostatin program for cardiometabolic ...

iBio, Inc., an innovator in precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment program by in-licensing a long-acting anti-myostatin antibody ...

The drug, known as an anti-latent myostatin, works by eliminating an inactive form of the protein from the blood. Roche plans to start a mid-stage trial this year combining the drug and its own ...

EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of ...

EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

--Elevai Labs, Inc., a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. EL ...